Kılıç, Erden

Profile Picture
Name Variants
K.,Erden
E., Kılıç
Kilic E.
E.,Kilic
E.,Kiliç
Erden, Kilic
E., Kilic
Erden, Kılıç
K., Erden
Kilic,E.
Kilic, Erden
Kılıç,E.
E., Kiliç
Kiliç, Erden
E.,Kılıç
Kılıç, Erden
Erden, Kiliç
Job Title
Profesor Doktor
Email Address
erden.kilic@atilim.edu.tr
Main Affiliation
Department Of Therapy and Rehabilitation
Status
Website
ORCID ID
0000-0001-6098-9576
Scopus Author ID
15052049100
Turkish CoHE Profile ID
Google Scholar ID
WoS Researcher ID
Scholarly Output

3

Articles

3

Citation Count

9

Supervised Theses

0

Filters

20221
Reset filters

Settings

Author: Duruöz,M.T.

Scholarly Output Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Article
    Citation - Scopus: 10
    Inconsistencies of the Disease Activity Assessment Tools for Psoriatic Arthritis: Challenges To Rheumatologists
    (Elsevier Masson s.r.l., 2022) Gezer,H.H.; Duruöz,M.T.; Nas,K.; Kılıç,E.; Sargın,B.; Kasman,S.A.; Tuncer,T.
    Objective: Currently, concerning the evaluation of psoriatic arthritis (PsA), there is no agreement on a standardized composite index for disease activity that includes all relevant domains. The present study sought to assess the rates of remission (REM)/low disease activity (LDA) and disease states [minimal disease activity (MDA), very low disease activity (VLDA)] as defined by diverse activity scales (DAPSA, DAS28-ESR) in an attempt to display discrepancies across these assessment tools for peripheral PsA. Methods: The study involved 758 patients (496 females, 262 males; mean age 47,1 years) with peripheral PsA who were registered to the Turkish League Against Rheumatism (TLAR) Network. The patients were assessed using the DAS28-ESR, DAPSA, MDA, and VLDA. The overall yield of each scale was assessed in identifying REM and LDA. The presence or absence of swollen joints was separately analysed. Results: The median disease duration was 4 years (range 0-44 years). According to DAPSA and DAS28-ESR, REM was achieved in 6.9% and 19.5% of the patients, respectively. The rates of MDA and VLDA were 16% and 2.9%, respectively. Despite the absence of swollen joints, a significant portion of patients were not considered to be in REM (296 (39.1%) patients with DAS28-ESR, 364 (48%) with DAPSA, and 394 (52%) with VLDA). Conclusion: Patients with peripheral PsA may be assigned to diverse disease activity levels when assessed with the DAS28-ESR, DAPSA, MDA and VLDA, which would inevitably have clinical implications. In patients with PsA a holistic approach seems to be necessary which includes other domains apart from joint involvement, such as skin involvement, enthesitis, spinal involvement, and patient-reported outcomes. © 2021 Société française de rhumatologie